ZZW-115 HCl | CAS#10122-45-9 (HCl) | NUPR1 inhibitor

MedKoo Cat#: 471109 | Name: ZZW-115 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ZZW-115 HCl is a potent NUPR1 inhibitor. ZZW-115 induces ferroptosis in a mitochondria-dependent manner. ZZW-115 induces ROS accumulation followed by a ferroptotic cell death, which could be prevented by ferrostatin-1 (Fer-1) and ROS-scavenging agents. In addition, ZZW-115-treatment increases the accumulation of hydroperoxided lipids in these cells. ZZW-115-induced mitochondrial morphological changes, compatible with the ferroptotic process, as well as mitochondrial network disorganization and strong mitochondrial metabolic dysfunction, which are rescued by both Fer-1 and N-acetylcysteine (NAC). Of note, the expression of TFAM, a key regulator of mitochondrial biogenesis, is downregulated by ZZW-115.

Chemical Structure

ZZW-115 HCl

CAS#10122-45-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 471109

Name: ZZW-115 HCl

CAS#: 10122-45-9 (HCl)

Chemical Formula: C24H34Cl3F3N4S

Exact Mass: 0.0000

Molecular Weight: 573.97

Elemental Analysis: C, 50.22; H, 5.97; Cl, 18.53; F, 9.93; N, 9.76; S, 5.59

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 500.00	2 Weeks
25mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

10122-45-9 (HCl) 801991-87-7 (free base)

Synonym

ZZW-115 HCl; ZZW115 HCl; ZZW 115 HCl; ZZW-115 hydrochloride

IUPAC/Chemical Name

N,N-dimethyl-4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazineethanamine, trihydrochloride

InChi Key

OBSKIDNFCBBXKJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H31F3N4S.3ClH/c1-28(2)12-13-30-16-14-29(15-17-30)10-5-11-31-20-6-3-4-7-22(20)32-23-9-8-19(18-21(23)31)24(25,26)27;;;/h3-4,6-9,18H,5,10-17H2,1-2H3;3*1H

SMILES Code

FC(C(C=C1N2CCCN3CCN(CCN(C)C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F.[H]Cl.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 573.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhang XY, Li SS, Gu YR, Xiao LX, Ma XY, Chen XR, Wang JL, Liao CH, Lin BL, Huang YH, Lian YF. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis. Mol Cancer. 2024 May 28;23(1):113. doi: 10.1186/s12943-024-02030-x. PMID: 38802795; PMCID: PMC11131253. 2: Li J, Liu J, Tang Y, Zhang H, Zhang Y, Zha X, Zhao X. Role of C/EBP Homologous Protein (CHOP) and Nupr1 Interaction in Endoplasmic Reticulum Stress- Induced Apoptosis of Lens Epithelial Cells. Mol Biotechnol. 2024 May 21. doi: 10.1007/s12033-024-01148-z. Epub ahead of print. PMID: 38771421. 3: Santofimia-Castaño P, Fraunhoffer N, Liu X, Bessone IF, di Magliano MP, Audebert S, Camoin L, Estaras M, Brenière M, Modesti M, Lomberk G, Urrutia R, Soubeyran P, Neira JL, Iovanna J. Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in KrasG12D-driven tumors. EMBO Mol Med. 2024 Mar;16(3):475-505. doi: 10.1038/s44321-024-00032-2. Epub 2024 Feb 15. PMID: 38360999; PMCID: PMC10940650. 4: Santofimia-Castaño P, Huang C, Liu X, Xia Y, Audebert S, Camoin L, Peng L, Lomberk G, Urrutia R, Soubeyran P, Neira JL, Iovanna J. NUPR1 protects against hyperPARylation-dependent cell death. Commun Biol. 2022 Jul 22;5(1):732. doi: 10.1038/s42003-022-03705-1. PMID: 35869257; PMCID: PMC9307593. 5: Rizzuti B, Lan W, Santofimia-Castaño P, Zhou Z, Velázquez-Campoy A, Abián O, Peng L, Neira JL, Xia Y, Iovanna JL. Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function. Biomolecules. 2021 Oct 3;11(10):1453. doi: 10.3390/biom11101453. PMID: 34680086; PMCID: PMC8533202. 6: Huang C, Santofimia-Castaño P, Liu X, Xia Y, Peng L, Gotorbe C, Neira JL, Tang D, Pouyssegur J, Iovanna J. NUPR1 inhibitor ZZW-115 induces ferroptosis in a mitochondria-dependent manner. Cell Death Discov. 2021 Oct 1;7(1):269. doi: 10.1038/s41420-021-00662-2. PMID: 34599149; PMCID: PMC8486797. 7: Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, Kroemer G, Tang D. NUPR1 is a critical repressor of ferroptosis. Nat Commun. 2021 Jan 28;12(1):647. doi: 10.1038/s41467-021-20904-2. PMID: 33510144; PMCID: PMC7843652. 8: Santofimia-Castaño P, Lan W, Xia Y, Zhou Z, Huang C, Barea D, Cervello M, Giannitrapani L, Montalto G, Peng L, Iovanna J. Response to the Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma" by Jiong Lin. Cancer Lett. 2021 Mar 1;500:161-162. doi: 10.1016/j.canlet.2020.12.001. Epub 2020 Dec 5. PMID: 33290870. 9: Lin J. Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma". Cancer Lett. 2021 Feb 28;499:1. doi: 10.1016/j.canlet.2020.11.020. Epub 2020 Nov 21. PMID: 33232790. 10: Lan W, Santofimia-Castaño P, Swayden M, Xia Y, Zhou Z, Audebert S, Camoin L, Huang C, Peng L, Jiménez-Alesanco A, Velázquez-Campoy A, Abián O, Lomberk G, Urrutia R, Rizzuti B, Geli V, Soubeyran P, Neira JL, Iovanna J. ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents. JCI Insight. 2020 Sep 17;5(18):e138117. doi: 10.1172/jci.insight.138117. PMID: 32780723; PMCID: PMC7526551. 11: Lan W, Santofimia-Castaño P, Xia Y, Zhou Z, Huang C, Fraunhoffer N, Barea D, Cervello M, Giannitrapani L, Montalto G, Peng L, Iovanna J. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. Cancer Lett. 2020 Aug 28;486:8-17. doi: 10.1016/j.canlet.2020.04.024. Epub 2020 May 21. PMID: 32446862. 12: Santofimia-Castaño P, Xia Y, Peng L, Velázquez-Campoy A, Abián O, Lan W, Lomberk G, Urrutia R, Rizzuti B, Soubeyran P, Neira JL, Iovanna J. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Cells. 2019 Nov 17;8(11):1453. doi: 10.3390/cells8111453. PMID: 31744261; PMCID: PMC6912534. 13: Santofimia-Castaño P, Xia Y, Lan W, Zhou Z, Huang C, Peng L, Soubeyran P, Velázquez-Campoy A, Abián O, Rizzuti B, Neira JL, Iovanna J. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019 Mar 28;129(6):2500-2513. doi: 10.1172/JCI127223. PMID: 30920390; PMCID: PMC6546470.